Schodack, NY, United States of America

George Y Lesher, Deceased


Average Co-Inventor Count = 3.4

ph-index = 3

Forward Citations = 221(Granted Patents)


Company Filing History:


Years Active: 1991-1996

Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovations of George Y. Lesher

Introduction

George Y. Lesher was a notable inventor whose contributions to the field of pharmaceuticals have left a lasting impact. He was based in Schodack, NY (US) and held a total of four patents during his career. His work primarily focused on developing compounds that have significant therapeutic applications, particularly in treating cardiovascular diseases and inhibiting malignant cell growth.

Latest Patents

Lesher's latest patents include the development of 6-heterocycyclyl pyrazolo[3,4-d]pyrimidin-4-ones and their compositions. These compounds are particularly useful in treating cardiovascular diseases and are synthesized through a specific reaction involving 5-amino-1H-pyrazole derivatives. Another significant patent involves a method of inhibiting mammalian topoisomerase II, which plays a crucial role in cancer treatment by inhibiting the growth of malignant cells.

Career Highlights

Throughout his career, George Y. Lesher worked with prominent companies such as Sterling Winthrop Inc. and Sterling Drug Inc. His innovative approaches and dedication to research have contributed to advancements in pharmaceutical sciences. His work has been recognized for its potential to improve treatment options for various diseases.

Collaborations

Lesher collaborated with notable colleagues, including Edward R. Bacon and Baldev Singh. These partnerships were instrumental in advancing his research and developing new therapeutic compounds.

Conclusion

George Y. Lesher's legacy as an inventor is marked by his significant contributions to pharmaceutical innovations. His patents continue to influence the field and provide valuable insights into the treatment of critical health issues.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…